Rings Bonded Directly To Each Other Patents (Class 562/469)
  • Publication number: 20150028217
    Abstract: In one embodiment, a scintillator includes a scintillator material; a primary fluor, and a Li-containing compound, where the Li-containing compound is soluble in the primary fluor, and where the scintillator exhibits an optical response signature for thermal neutrons that is different than an optical response signature for fast neutrons and gamma rays.
    Type: Application
    Filed: April 15, 2014
    Publication date: January 29, 2015
    Applicant: Lawrence Livermore National Sercurity, LLC
    Inventors: Natalia P. Zaitseva, M. Leslie Carman, Michelle A. Faust, Andrew M. Glenn, H. Paul Martinez, Stephen A. Payne
  • Publication number: 20150018422
    Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: February 12, 2013
    Publication date: January 15, 2015
    Inventors: Seiji Miwatashi, Hideo Suzuki, Tomohiro Okawa, Yasufumi Miyamoto, Takeshi Yamasaki, Yuko Hitomi, Yasuhiro Hirata, Akito Shibuya
  • Patent number: 8915989
    Abstract: The porous coordination polymer of the invention contains metal complexes formed by coordination bonding between a trivalent metal ion and an aromatic tricarboxylic acid represented by formula (1). The porous coordination polymer also has a pore structure formed by integration of a plurality of the metal complexes. [In formula (1), n represents an integer of 0 to 4.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: December 23, 2014
    Assignee: JX Nippon Oil & Energy Corporation
    Inventors: Daisuke Watanabe, Shinji Oshima, Rudy Coquet, Susumu Kitagawa
  • Publication number: 20140364641
    Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.
    Type: Application
    Filed: January 9, 2014
    Publication date: December 11, 2014
    Applicant: ENVIVO PHARMACEUTICALS, INC.
    Inventors: Gideon SHAPIRO, Richard CHESWORTH
  • Publication number: 20140221469
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use.
    Type: Application
    Filed: September 10, 2012
    Publication date: August 7, 2014
    Applicants: Otsuka Pharmaceutical Co., Ltd., GW Pharma Limited
    Inventors: Ruth Alexandra Ross, Daniela Parolaro
  • Publication number: 20140187786
    Abstract: Compounds that are 1,3,4-trisubstituted benzenes which modulate (e.g., inhibit) the activity of ?-secretase. The compounds are expected to reduce the level of A?42 in patients and be useful in the treatment of diseases (e.g., Alzheimer's disease) characterized by elevated levels of A?42 and/or the formation of A? plaques.
    Type: Application
    Filed: July 18, 2013
    Publication date: July 3, 2014
    Applicant: EnVivo Pharmaceuticals, Inc.
    Inventors: Gideon Shapiro, Richard Chesworth
  • Patent number: 8664249
    Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: March 4, 2014
    Assignee: EnVivo Pharmaceuticals, Inc.
    Inventors: Gideon Shapiro, Richard Chesworth
  • Publication number: 20130280401
    Abstract: The present invention relates to the use of one or more compounds of the formulae and/or pharmaceutically acceptable salts thereof for inhibiting the oxidation of fatty acids and/or triacylglycerols; and/or the rancidification of products that includes one or more of fatty acids and/or one or a plurality of triacylglycerols; and/or chemical and/or sensory changes of products that includes one or more of fatty acids and/or one or a plurality of triacylglycerols, caused by the action of the oxygen of the air. Corresponding mixtures and orally consumable preparations and methods are also described.
    Type: Application
    Filed: April 14, 2013
    Publication date: October 24, 2013
    Inventor: Symrise AG
  • Patent number: 8546392
    Abstract: The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: October 1, 2013
    Assignee: Universitaet des Saarlandes
    Inventors: Rolf Hartmann, Martin Frotscher, Sandrine Oberwinkler, Erika Ziegler, Josef Messinger, Heinrich-Hubert Thole
  • Publication number: 20130253004
    Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
    Type: Application
    Filed: December 6, 2011
    Publication date: September 26, 2013
    Applicant: Amira Pharmaceuticals, Inc.
    Inventors: Thomas Jon Seiders, Bowei Wang, John Howard Hutchinson, Nicholas Simon Stock, Deborah Volkots
  • Publication number: 20130165486
    Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.
    Type: Application
    Filed: February 1, 2013
    Publication date: June 27, 2013
    Applicant: ENVIVO PHARMACEUTICALS, INC.
    Inventor: ENVIVO PHARMACEUTICALS, INC.
  • Patent number: 8470075
    Abstract: Disclosed are tetratopic carboxylic acid phenyl for use in metal-organic framework compounds. These compounds are useful in catalysis, gas storage, sensing, biological imaging, drug delivery and gas adsorption separation.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: June 25, 2013
    Assignee: Northwestern University
    Inventors: Omar K. Farha, Joseph T. Hupp
  • Publication number: 20130129608
    Abstract: The porous coordination polymer of the invention contains metal complexes formed by coordination bonding between a trivalent metal ion and an aromatic tricarboxylic acid represented by formula (1). The porous coordination polymer also has a pore structure formed by integration of a plurality of the metal complexes. [In formula (1), n represents an integer of 0 to 4.
    Type: Application
    Filed: June 23, 2011
    Publication date: May 23, 2013
    Applicant: JX NIPPON OIL & ENERGY CORPORATION
    Inventors: Daisuke Watanabe, Shinji Oshima, Rudy Coquet, Susumu Kitagawa
  • Publication number: 20130122297
    Abstract: Disclosed herein is a way to produce a series of discrete sized slender, rigid oligoparaxylene molecules ranging from 1-5 nm in length. Molecules, based on 1-7, 9-11 paraxylene rings, have been synthesized as part of a homologous series of oligoparaxylenes (OPXs) with a view to providing a molecular tool box for the construction of nano architectures—such as spheres, cages, capsules, metal-organic frameworks (MOFs), metal-organic polyhedrons (MOPs) and covalent-organic frameworks (COFs), to name but a few—of well-defined sizes and shapes. Twisting between the planes of contiguous paraxylene rings is generated by the steric hindrance associated with the methyl groups and leads to the existence of soluble molecular gauge blocks without the need—at least in the case of the lower homologues—to introduce long aliphatic side chains onto the phenylene rings in the molecules.
    Type: Application
    Filed: October 24, 2012
    Publication date: May 16, 2013
    Applicant: NORTHWESTERN UNIVERSITY
    Inventor: NORTHWESTERN UNIVERSITY
  • Publication number: 20130096210
    Abstract: The disclosure relates to metal organic frameworks or isoreticular metal organic frameworks, methods of production thereof, and methods of use thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
  • Patent number: 8367863
    Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: February 5, 2013
    Assignee: EnVivo Pharmaceuticals, Inc.
    Inventors: Gideon Shapiro, Richard Chesworth
  • Publication number: 20130018202
    Abstract: The present invention relates to novel 4-biphenyl-substituted pyrazolidine-3,5-dione derivatives of the formula (I) in which A, D, G, W, X, Y and Z are as defined above, to a plurality of processes for the preparation and to their use as pesticides and/or herbicides and/or microbicides. Moreover, the invention relates to selective herbicidal compositions comprising both the 4-biphenyl-substituted pyrazolidine-3,5-dione derivatives of the formula (I) and a crop plant compatibility-improving compound.
    Type: Application
    Filed: January 11, 2012
    Publication date: January 17, 2013
    Applicant: Bayer CropScience AG
    Inventors: Reiner Fischer, Thomas Bretschneider, Ernst Rudolf F. Gesing, Dieter Feucht, Karl-Heinz Kuck, Peter Lösel, Olga Malsam, Christian Arnold, Thomas Auler, Martin Jeffrey Hills, Heinz Kehne
  • Publication number: 20120330056
    Abstract: A method for preparing aromatic carboxylic acid derivatives by nucleophilic aromatic substitution, involves reacting an aromatic carboxylic acid derivative supporting only one carboxyl function, or one of the salts thereof, the carboxylic acid derivative supporting, orthogonally to the carboxyl function, a leaving group which is a fluorine or chlorine atom or an alkoxy group, chiral or otherwise and, in the latter case, preferably a methoxy group; the carboxylic acid derivative being substituted by at least one electro-attractive group other than the leaving group, preferably by a fluorine atom, with a MNu reagent, wherein M is a metal and Nu an optionally chiral nucleophile, the nucleophilic aromatic substitution reaction being carried out without a catalyst and without a step of protecting/unprotecting the acid function of the initial compound, the method being selective in that the reaction leads to the formation of ketone derivatives in a very minority fashion during the reaction.
    Type: Application
    Filed: February 18, 2011
    Publication date: December 27, 2012
    Applicants: UNIVERSITE DU MAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jacques Mortier, Anne-Sophie Castanet, Arnaud Nourry, Mickael Belaud-Rotureau
  • Patent number: 8262775
    Abstract: Disclosed are tetratopic carboxylic acid phenyl for use in metal-organic framework compounds. These compounds are useful in catalysis, gas storage, sensing, biological imaging, drug delivery and gas adsorption separation.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: September 11, 2012
    Assignee: Northwestern University
    Inventors: Omar K. Farha, Joseph T. Hupp
  • Patent number: 8217064
    Abstract: Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: July 10, 2012
    Assignee: EnVivo Pharmaceuticals, Inc.
    Inventors: Gideon Shapiro, Richard Chesworth
  • Patent number: 8217027
    Abstract: The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: July 10, 2012
    Assignee: Abbott Laboratories
    Inventors: Grier A. Wallace, Eric C. Breinlinger, Kevin P. Cusack, Shannon R. Fix-Stenzel, Thomas D. Gordon, Adrian D. Hobson, Martin E. Hayes, Graham K. Ansell, Pintipa Grongsaard
  • Publication number: 20120059062
    Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: GW Pharma Limited
    Inventors: Brian Whittle, Farideh Afshin Javid
  • Patent number: 8106235
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: January 31, 2012
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • Patent number: 8106236
    Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 31, 2012
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Yung Ho
  • Publication number: 20120018672
    Abstract: The invention provides a liquid crystal compound having a high stability to heat, light or the like, a wide temperature range of a nematic phase, a small viscosity, a large optical anisotropy and a suitable elastic constant K33, and further having a suitable negative dielectric anisotropy and an excellent compatibility with other liquid crystal compounds. The invention also provides a liquid crystal composition including this liquid crystal compound and a liquid crystal display device containing this liquid crystal composition. A liquid crystal compound represented by formula (a): For example, Ra and Rb are alkyl having 1 to 10 carbons, alkenyl having 2 to 10 carbons or alkoxy having 1 to 9 carbons; the ring A1 and the ring A2 are 1,4-phenylene or trans-1,4-cyclohexylene; L1, L2, L3 and L4 are hydrogen or fluorine, and at least three of them are fluorine; and Z1 and Z2 are a single bond, —(CH2)2—, —CH?CH—, —CH2O— or —OCH2—.
    Type: Application
    Filed: January 12, 2010
    Publication date: January 26, 2012
    Applicants: CHISSO PETROCHEMICAL CORPORATION, JNC CORPORATION
    Inventor: Masahide Kobayashi
  • Patent number: 8093385
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: January 10, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Romyr Dominique, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri
  • Patent number: 8076324
    Abstract: The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: December 13, 2011
    Assignee: Sanofi-Aventis
    Inventors: Thomas Bohme, Uwe Gerlach, Dirk Gretzke, Heinz-Werner Kleemann, Stefania Pfeiffer-Marek, Henning Vollert, Jean-Michel Altenburger, Sergio Mallart
  • Publication number: 20110288175
    Abstract: 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.
    Type: Application
    Filed: August 8, 2011
    Publication date: November 24, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Luca RAVEGLIA, Ilaria Peretto, Stefano Radaelli, Bruno Pietro Imbimbo, Andrea Rizzi, Gino Villetti
  • Patent number: 8049034
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: November 1, 2011
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • Patent number: 8044236
    Abstract: A compound represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof having an inhibitory action against plasminogen activator inhibitor-1 (PAI-1): wherein R1 represents a C6-10 aryl group; or a substituted C6-10 aryl group, R2 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, nitro group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group, a phenyl group and carboxy group, X represents —CH2—, —CH2CH2—, —CH?CH— or —N(R3)—C(?O)—, Y represents carboxy group or a bioisostere of carboxy group, R3 represents hydrogen atom, a C1-4 alkyl group or a C7-12 aralkyl group, m represents 0 or 1.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: October 25, 2011
    Assignee: Institute of Medicinal Molecular Design, Inc.
    Inventors: Youichi Yamaguchi, Takeshi Yanase, Susumu Muto, Akiko Itai
  • Publication number: 20110131029
    Abstract: Provided are the expression method of influenza virus polymerase PAc-PB1N complex, the co-crystallization method of the complex and the three-dimendional structure of the crystal of PAc-PB1N complex. Also provided are the compounds binding to the influenza virus polymerase PAc and the expression method of influenza virus polymerase PAN. The three-dimensional structure of the crystal of PAc-PB1N complex can be used for screening and designing the drug for the treatment of influenza.
    Type: Application
    Filed: February 22, 2009
    Publication date: June 2, 2011
    Inventors: Yingfang Liu, Xiaojing He, Zonghao Zeng, Jie Zhou
  • Publication number: 20110105545
    Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 5, 2011
    Applicant: FIBROSTATIN, S.L.
    Inventors: JUAN SAUS, SANTOS FUSTERO, JUAN F. SANZ-CERVERA, ENRIQUE PEREZ-PAYA, RAUL BLASCO, FRANCISCO REVERT-ROS, FERNANDO REVERT
  • Publication number: 20110087043
    Abstract: The present invention relates to compounds of structural formula I as site-specific inhibitors of histone methyltransferase, where R1 and R1 is —OCH3 or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula Ia, where R1 and R1 is —OCH3, R2 and R2 is —OH; a process of preparation of compound of structural formula Ib, where R1 and R1 is —OCH3, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.
    Type: Application
    Filed: October 15, 2010
    Publication date: April 14, 2011
    Inventors: Tapas Kumar Kundu, Ruthrotha Selvi Bharatha Vikru, Hari Kishore Annavarapu, Mantelingu Kempegowda
  • Patent number: 7897643
    Abstract: The present disclosure relates to compounds having the general Formula (I) with the definitions of R1, R2, R3, and R4 as provided herein, and/or salts thereof. The disclosure also relates to the use of such compounds for the treatment of Alzheimer's disease, and for the modulation of ?-secretase activity.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: March 1, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventor: Chih Yung Ho
  • Publication number: 20110040094
    Abstract: Compounds that are 1,3,4-trisubstituted benzenes which modulate (e.g., inhibit) the activity of ?-secretase. The compounds are expected to reduce the level of A?42 in patients and be useful in the treatment of diseases (e.g., Alzheimer's disease) characterized by elevated levels of A?42 and/or the formation of A? plaques.
    Type: Application
    Filed: September 15, 2008
    Publication date: February 17, 2011
    Applicant: ENVIVO PHARMACEUTICALS, INC.
    Inventors: Gideon Shapiro, Richard Chesworth
  • Patent number: 7884133
    Abstract: Cannabinoid derivatives are known for their function in the central as well as peripheral nervous system. Disclosed are some novel (+)-cannabidiol (CBD) derivatives of the general formula (I) having selective activity in the peripheral, but not in the central nervous system. Use of (+)-CBD derivatives as analgesics, anti-inflammatory and anti-diarrheal agents is also disclosed.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: February 8, 2011
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Ariel Ltd.
    Inventors: Raphael Mechoulam, Ester Fride
  • Publication number: 20100292498
    Abstract: The present invention relates to compounds of structural formula (I) as site-specific inhibitor of histone methyl-transferase, where R1 and R1 is —OCH or —OH, R2 and R2 is —OH or —OAc; a process of isolating compound of structural formula (Ia), where R1 and R1 is —OCH, R2 and R2 is —OH; a process of preparation of compound of structural formula (Ib), where R1 and R1 is —OCH, R2 and R2 is —OAc; a process of preparation of compound of structural formula Ic, where R1 and R1 is —OH, R2 and R2 is —OH; and use of compounds of structural formula I for manufacture of a medicament for management of cancer and/or disease conditions in a subject in need thereof.
    Type: Application
    Filed: June 26, 2007
    Publication date: November 18, 2010
    Applicant: Jawaharlal Nehru Centre For Advanced Scientific Research
    Inventors: Tapas Kumar Kundu, Ruthrotha Selvi Bharatha Vikru, Hari Kishore Annavarapu, Matelingu Kempegowda
  • Patent number: 7834013
    Abstract: The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 16, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: David Francis Corbett, Kate Anna Dwornik, Dulce Maria Garrido, Stephen Carl McKeown, Wendy Yoon Mills, Andrew James Peat, Terrence Lee Smalley, Jr.
  • Patent number: 7816385
    Abstract: A novel class of dicarboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator -Activated Receptors (PPAR).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 19, 2010
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Per Sauerberg, Lone Jeppesen, Zdenek Polivka, Karel Sindelar
  • Patent number: 7803835
    Abstract: The present invention relates generally to substituted acetic acid derivatives and methods of using them.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: September 28, 2010
    Assignee: Wyeth LLC
    Inventors: Ariamala Gopalsamy, Scott Lee Kincaid
  • Publication number: 20100240678
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification.
    Type: Application
    Filed: March 10, 2010
    Publication date: September 23, 2010
    Inventors: Romyr Dominique, Robert Alan Goodnow, JR., Agnieszka Kowalczyk, Qi Qiao, Achyutharao Sidduri, Jefferson Wright Tilley
  • Publication number: 20100204234
    Abstract: The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.
    Type: Application
    Filed: March 27, 2008
    Publication date: August 12, 2010
    Inventors: Rolf Hartmann, Martin Frotscher, Sandrine Oberwinkler, Erika Ziegler, Josef Messinger, Heinrich-Hubert Thole
  • Publication number: 20100204206
    Abstract: Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 3, 2009
    Publication date: August 12, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Thomas BOHME, Uwe GERLACH, Dirk GRETZKE, Heinz-Werner KLEEMANN, Stefania PFEIFFER-MAREK, Henning VOLLERT, Jean-Michel ALTENBURGER, Sergio MALLART
  • Publication number: 20100168448
    Abstract: The invention relates to methods of preparing cannabinoids in substantially pure form starting from plant material. Also described are substantially pure preparations of various cannabinoids and cannabinoid acids, and also extracts enriched in cannabinoids and cannabinoid acids.
    Type: Application
    Filed: March 1, 2010
    Publication date: July 1, 2010
    Applicant: GW Pharma Limited
    Inventors: Ian Flockhart, Gary William Wheatley, Su Dring, Leslie Archer
  • Publication number: 20090286776
    Abstract: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these compounds.
    Type: Application
    Filed: July 23, 2009
    Publication date: November 19, 2009
    Inventors: Jean Jacques ZEILLER, Hervè Dumas, Valérie Guyard-Dangremont, Isabelle Berard, Francis Contard, Daniel Guerrier, Gérard Ferrand, Yves Bonhomme
  • Publication number: 20090239869
    Abstract: Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.
    Type: Application
    Filed: March 16, 2009
    Publication date: September 24, 2009
    Applicant: ALLERGAN, INC.
    Inventors: Yariv Donde, Robert M. Burk, Jeremiah H. Nguyen
  • Patent number: 7585895
    Abstract: Therapeutic prostaglandin compounds are disclosed herein.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: September 8, 2009
    Assignee: Allergan, Inc.
    Inventors: Yariv Donde, Robert M. Burk
  • Publication number: 20090176973
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: June 18, 2008
    Publication date: July 9, 2009
    Inventors: Kevin J. Duffy, Connie Erickson-Miller, Daniel F. Eppley, Julian Jenkins, Juan I. Luengo, Nannan Liu, Alan T. Price, Antony N. Shaw, Sophie Visonneau, Kenneth Wiggall
  • Publication number: 20090137561
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 28, 2009
    Applicant: Amgen Inc.
    Inventors: Sean P. Brown, Qiong Cao, Paul John Dransfield, Xiaohui Du, Jonathan Houze, Xian Yun Jiao, Yong-Jae Kim, Todd J. Kohn, SuJen Lai, An-Rong Li, Daniel Lin, Jian Luo, Julio C. Medina, Jeffrey D. Reagan, Vatee Pattaropong, Margrit Schwarz, Wang Shen, Yongli Su, Gayathri Swaminath, Marc Vimolratana, Xiang Wang, Yumei Xiong, Li Yang, Ming Yu, Jie Zhang, Liusheng Zhu
  • Patent number: RE43372
    Abstract: Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: May 8, 2012
    Assignee: Duke University
    Inventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De